HLA-G expression and regulation during Pseudomonas aeruginosa infection in cystic fibrosis patients

Future Microbiology

Volumn 11, Issue 3, 2016, Pages 363-373

  Rizzo, Roberta ^a   Bergamini, Gabriella ^a,b   Bortolotti, Daria ^a   Leal, Teresinha ^c   D'Orazio, Ciro ^d   Pintani, Emily ^d   Melchiorri, Loredana ^a   Zavatti, Eleonora ^e   Assael, Baroukh M ^d   Sorio, Claudio ^b   Melotti, Paola ^d  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

^e UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

cystic fibrosis; HLA G; Pseudomonas aeruginosa

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HLA G ANTIGEN; HLA G1 ANTIGEN; HLA G5 ANTIGEN; PENTRAXIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; HLA ANTIGEN CLASS 1; Q SURFACE ANTIGENS;

ACUTE PHASE RESPONSE; ADULT; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; FORCED EXPIRATORY VOLUME; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUNG FIBROSIS; MALE; MOUSE; MURINE MODEL; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; SPUTUM CULTURE; STAPHYLOCOCCUS INFECTION; WILD TYPE; ANIMAL; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHUS; CELL LINE; COMPLICATION; CYSTIC FIBROSIS; DISEASE MODEL; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG; MICROBIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY MUCOSA;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTI-BACTERIAL AGENTS; BRONCHI; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-G ANTIGENS; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLAMMATION; LUNG; MICE; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY MUCOSA;

EID: 84962469203     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.15.143     Document Type: Article

References (32)

1. Pritt B, O'Brien L, Winn W. Mucoid pseudomonas in cystic fibrosis. Am. J. Clin. Pathol. 128(1), 32-34 (2007).
2. Rajan S, Saiman L. Pulmonary infections in patients with cystic fibrosis. Semin. Respir. Infect. 17, 47-56 (2002).
3. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407, 762-764 (2000).
4. HØiby N, Krogh Johansen H, Moser C, Song Z, Ciofu O, Kharazmi A. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect. 3, 23-35 (2001).
5. Lovewell RR, Yash R, Berwin B. Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa. Am. J. Physiol. Lung Cell Mol. Physiol. 306(7), L591-L603 (2014).
6. Sallenave JM. Phagocytic and signaling innate immune receptors: are they dysregulated in cystic fibrosis in the fight against Pseudomonas aeruginosa? Int. J. Biochem. Cell Biol. 52, 103-107. (2014).
7. Borghi A, Fogli E, Stignani M et al. Soluble human leukocyte antigen-G and interleukin-10 levels in plasma of psoriatic patients: preliminary study on a possible correlation between generalized immune status, treatments and disease. Arch. Dermatol. Res. 300(10), 551-559 (2008).
8. Mapp CE, Ferrazzoni S, Rizzo R et al. Soluble human leucocyte antigen-G and interleukin-10 levels in isocyanate-induced asthma. Clin. Exp. Allergy 39(6), 812-819 (2009).
9. Rizzo R, Mapp CE, Melchiorri L et al. Defective production of soluble HLA-G molecules by peripheral blood monocytes in patients with asthma. J. Allergy Clin. Immunol. 115(3), 508-513 (2005).
10. White SR, Loisel DA, Stern R, Laxman B, Floreth T, Marroquin BA. Human leukocyte antigen-G expression in differentiated human airway epithelial cells: lack of modulation by Th2-associated cytokines. Respir. Res. 14, 4 (2013).
11. Rizzo R, Bortolotti D, Bolzani S, Fainardi E. HLA-G molecules in autoimmune diseases and infections. Front Immunol. 5, 592 (2014).
12. Rizzo R, Trentini A, Bortolotti D et al. Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding. Mol. Cell Biochem. 381(1-2), 243-255 (2013).
13. Hviid TV, Rizzo R, Christiansen OB, Melchiorri L, Lindhard A, Baricordi OR. HLA-G and IL-10 in serum in relation to HLA-G genotype and polymorphisms. Immunogenetics 56(3), 135-141 (2004).
14. Rizzo R, Hviid TV, Stignani M et al. The HLA-G genotype is associated with IL-10 levels in activated PBMCs. Immunogenetics 57(3-4), 172-181 (2005).
15. Rizzo R, Vercammen M, van De Velde H, Horn PA, Rebmann V. The importance of HLA-G expression in embryos, trophoblast cells, and embryonic stem cells. Cell Mol. Life Sci. 68(3), 341-352 (2011).
16. Chiusolo P, Bellesi S, Piccirillo N et al. The role of HLA-G 14-bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis. Bone Marrow Transplant. 47(1), 120-124 (2012).
17. Bortolotti D, Gentili V, Rotola A, Di Luca D, Rizzo R. Implication of HLA-G 3' untranslated region polymorphisms in human papillomavirus infection. Tissue Antigens 83(2), 113-118 (2014).
18. Jiang Y, Chen S, Jia S et al. Association of HLA-G 3' UTR 14-bp insertion/deletion polymorphism with hepatocellular carcinoma susceptibility in a chinese population. DNA Cell Biol. 30(12), 1027-1032 (2011).
19. White SR, Loisel DA, Mcconville JF et al. Levels of soluble human leukocyte antigen-G are increased in asthmatic airways. Eur. Respir J. 35(4), 925-927 (2010).
20. Melen E, Kho AT, Sharma S et al. Expression analysis of asthma candidate genes during human and murine lung development. Respir. Res. 12, 86 (2011).
21. Doring G, Conway SP, Heijerman HG et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir J. 16(4), 749-767 (2000).
22. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Eur. Respir. J. 6(Suppl. 16), 5-40 (1993).
23. Bergamini G, Di Silvestre D, Mauri P et al. Mudpit analysis of released proteins in Pseudomonas aeruginosa laboratory and clinical strains in relation to proinflammatory effects. Integr. Biol. (Camb.) 4(3), 270-279 (2012).
24. Fainardi E, Rizzo R, Melchiorri L et al. Soluble HLA-G molecules are released as HLA-G5 and not as soluble HLA-G1 isoforms in CSF of patients with relapsingremitting multiple sclerosis. J. Neuroimmunol. 192(1-2), 219-225 (2007).
25. Rizzo R, Bortolotti D, Fredj NB et al. Role of HLA-G 14bp deletion/insertion and +3142C>G polymorphisms in the production of sHLA-G molecules in relapsing-remitting multiple sclerosis. Hum. Immunol. 73(11), 1140-1146 (2012).
26. Joshi A, Perin DP, Gehle A, Nsiah-Kumi PA. Feasibility of using C-reactive protein for point-of-care testing. Technol. Health Care 21(3), 233-240 (2013).
27. Liang Y, Yeligar SM, Brown LA. Exhaled breath condensate: a promising source for biomarkers of lung disease. ScientificWorldJournal 2012, 217518 (2012).
28. Quinton PM. Physiological basis of cystic fibrosis: a historical perspective. Physiol. Rev. 79(1), S3-S22 (1999).
29. Onno M, Pangault C, Le Friec G, Guilloux V, Andre P, Fauchet R. Modulation of HLA-G antigens expression by human cytomegalovirus: specific induction in activated macrophages harboring human cytomegalovirus infection. J. Immunol. 164(12), 6426-6434 (2000).
30. Lemaoult J, Rouas-Freiss N, Carosella ED. Immuno-tolerogenic functions of HLA-G: relevance in transplantation and oncology. Autoimmun. Rev. 4(8), 503-509 (2005).
31. Ciornei CD, Novikov A, Beloin C et al. Biofilm-forming Pseudomonas aeruginosa bacteria undergo lipopolysaccharide structural modifications and induce enhanced inflammatory cytokine response in human monocytes. Innate Immun. 16(5), 288-301 (2010).
32. Porto I, Mendes-Junior CT, Felício L et al. MicroRNAs targeting the immunomodulatory HLA-G gene: a new survey searching for micrornas with potential to regulate HLA-G. Mol. Immunol. 65(2), 230-241 (2015).